LONESTAR研究：晚期非小细胞肺癌纳武利尤单抗（Nivolumab）+伊匹木单抗（Ipilimumab）治疗后的局部巩固治疗（Local Consolidation Therapy）
NCT 03391869 (LONESTAR) Randomized Phase III Trial of Local Consolidation Therapy After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients with Metastatic Non-Small Cell Lung Cancer -Strategic Alliance: BMS. Primary outcome measure is overall survival. Estimated enrollment is 270 patients. |
|
